https://www.forbes.com/sites/kevinholdenplatt/2025/12/31/space-startup-aims-to-genetically-enhance-astronauts-for-mars-odysseys/
Space Startup Aims To Genetically Enhance Astronauts For Mars Odysseys
Updated Jan 01, 2026, 09:43am EST
Even as a rocket revolution sets the stage for astronauts to begin exploring Mars, radical advancements in bioengineering could help them survive the cosmic bullets that pelt interplanetary spacecraft and the Martian dunes, says a top American scholar on genomics and space biology.
Professor Christopher Mason told me in an interview the space biomedicine outfit that he co-heads, BioAstra, aims to test potential countermeasures to the DNA-threatening cosmic rays shot out by exploding supernovas that can bombard crew capsules that fly beyond the Earth’s life-protecting magnetic shield.
A professor of genomics and computational biomedicine at prestigious Weill Cornell Medicine, Mason says BioAstra intends to map out these defensive measures during a three-part series of space missions - to low Earth orbit, around the Moon, and then while circling Mars.
A revolution in perfecting reusable rockets - spearheaded by SpaceX and now Blue Origin - is giving rise to a “Second Space Age” that will see waves of independent aeronauts lift off to commercial space stations being designed to ring the planet, and to the cratered topography of the Moon, says Mason, who is chairman of BioAstra.
The take-off of rockets that can serially launch promises to democratize spaceflight and open the way to interplanetary treks by spacefarers across and beyond the astronaut corps of NASA and the other national space agencies.
The invention of recoverable boosters, he says, is setting the stage for a Big Bang-like expansion in space expeditions ahead.
This spacecraft revolution “has created a new biomedical imperative” to protect astronauts as they fly through bombardments of radiation and beyond the force of gravity generated by the Earth.
In a captivating study that he headed on the new-millennium race into space, Professor Mason states:
“The recent acceleration of commercial, private, and multinational spaceflight has created an unprecedented level of activity in low Earth orbit (LEO), concomitant with the highest-ever number of crewed missions entering space and preparations for exploration-class (>1 year) missions.”
“Such rapid advancement into space from many new companies, countries, and space-related entities has enabled a Second Space Age.”
“This new era is also poised to leverage, for the first time, modern tools and methods of molecular biology and precision medicine,” Professor Mason adds, “thus enabling precision aerospace medicine for the crews.”
Scholars across the U.S., Japan, Sweden, Greece, Austria, Poland and Chile all teamed up to conduct the Second Space Age study, which reflects a worldwide interest in leveraging, "for the first time, modern tools and methods of molecular biology and precision medicine, thus enabling precision aerospace medicine for the crew” on deep-space flights.
This global ring of scholars, he told me, “had members across multiple space agencies,” including NASA, the European Space Agency and the Japan Aerospace Exploration Agency, signaling the skyrocketing importance of harnessing advances in biotechnology to safeguard future astronauts around the world.
“I think there is an extraordinary burst of industry, academic, NGO, and government interest that will accelerate spaceflight and space research to a new era.”
“Precision medicine is the standard already for terrestrial medicine (pharmacogenomics),” Professor Mason says, and “it will soon be the same for spaceflight.”
1/3